| Gammanorm (human immune globulin subcutaneous) / Octapharma |
NCT02111590: Immunoglobulin Dosage and Administration Form in CIDP and MMN |
|
|
| Completed | N/A | 36 | Europe | Immunoglobulins, Gammanorm(R), immunoglobulin for subcutaneous use | Rigshospitalet, Denmark, Aarhus University Hospital, Octapharma Pharmazeutika Produktionsges.m.b.H. | Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, Hemolytic Anemia | 07/15 | 07/15 | | |
NCT03369301: The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency |
|
|
| Completed | N/A | 102 | Europe | Gammanorm, Other Subcutaneous Immunoglobulins | Octapharma | Secondary Immune Deficiency | 11/19 | 11/19 | | |
NCT03656640: Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases |
|
|
| Terminated | N/A | 60 | Europe, RoW | Gammanorm | Octapharma | Autoimmune Diseases | 12/19 | 12/19 | | |
NCT05986734: Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies |
|
|
| Recruiting | N/A | 100 | RoW | Cutaquig, subcutaneous immunoglobulin, Octapharma | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Primary Immunodeficiency Diseases (PID) | 07/23 | 12/23 | | |
NCT04354129: Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency. |
|
|
| Recruiting | N/A | 30 | Canada | Cutaquig®, Immunoglobulin (human) subcutaneous 16.5% Solution for injection (165 mg/mL) | University of Alberta, Octapharma | Primary Immune Deficiency Disorder, Secondary Immune Deficiency | 06/24 | 06/24 | | |
